Medical Policy  
**Intraoperative Radiotherapy**

**Table of Contents**
- Policy: Commercial
- Policy: Medicare
- Authorization Information
- Coding Information
- Description
- Policy History
- Information Pertaining to All Policies
- References

**Policy Number:** 278  
BCBSA Reference Number: 8.01.08  
NCD/LCD: N/A

**Related Policies**
Accelerated Breast Irradiation after Breast-Conserving Surgery for Early Stage Breast Cancer and Breast Brachytherapy, #326

**Policy**
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity  
Medicare HMO Blue℠ and Medicare PPO Blue℠ Members

Use of intraoperative radiotherapy may be considered **MEDICALLY NECESSARY** in the following situation:
- Rectal cancer with positive or close margins with T4 lesions or recurrent disease.

Use of intraoperative radiotherapy is considered **INVESTIGATIONAL** for all other oncologic applications.

**Prior Authorization Information**

**Inpatient**
- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

**Outpatient**
- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

<table>
<thead>
<tr>
<th>Service Type</th>
<th>Authorization Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial Managed Care (HMO and POS)</td>
<td>Prior authorization is <strong>not required</strong>.</td>
</tr>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>Prior authorization is <strong>not required</strong>.</td>
</tr>
<tr>
<td>Medicare HMO Blue℠</td>
<td>Prior authorization is <strong>not required</strong>.</td>
</tr>
<tr>
<td>Medicare PPO Blue℠</td>
<td>Prior authorization is <strong>not required</strong>.</td>
</tr>
</tbody>
</table>
CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

<table>
<thead>
<tr>
<th>CPT codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>77424</td>
<td>Intraoperative radiation treatment delivery, x-ray, single treatment session</td>
</tr>
<tr>
<td>77425</td>
<td>Intraoperative radiation treatment delivery, electrons, single treatment session</td>
</tr>
</tbody>
</table>

ICD-10 Procedure Codes

<table>
<thead>
<tr>
<th>ICD-10-PCS-procedure codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>DDY7CZZ</td>
<td>Intraoperative Radiation Therapy (IORT) of Rectum</td>
</tr>
</tbody>
</table>

The following ICD Diagnosis Codes are considered medically necessary when submitted with the CPT codes above if medical necessity criteria are met:

ICD-10 Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10-CM diagnosis codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C20</td>
<td>Malignant Neoplasm Of Rectum</td>
</tr>
<tr>
<td>D01.2</td>
<td>Carcinoma In Situ Of Rectum</td>
</tr>
</tbody>
</table>

Description

Intraoperative radiotherapy (IORT) increases the intensity of radiation delivered directly to tumors. The tumor and associated tissues at risk for micrometastatic spread are directly visualized during surgery. IORT is delivered directly to the tumor, and normal or uninvolved tissues are not exposed to radiation because they are removed or shielded from the treatment field.

Summary

Intraoperative radiotherapy (IORT) is delivered directly to exposed tissues during surgery and may allow higher radiation doses by excluding nearby radiation dose-sensitive tissues. Different IORT modalities are available that impact both the dose distribution and method of application. IORT techniques include electron beam IORT, high-dose rate brachytherapy based IORT, and low-energy x-ray IORT.

For individuals who have rectal cancer who receive adjunctive IORT, the evidence includes randomized controlled trials (RCTs), nonrandomized comparative studies, and systematic reviews of these studies. Relevant outcomes are overall survival (OS), disease-specific survival, change in disease status, and treatment-related morbidity. Adjunctive use of IORT as part of a multimodal treatment could permit an increase in radiation dose without increasing complications. However, a phase 3 RCT and meta-analysis of IORT for locally advanced rectal cancer did not find improved outcomes with IORT in combination with external-beam radiotherapy (EBRT) and surgery. One systematic review evaluating locally advanced and recurrent rectal cancers together, has shown a significant benefit with addition of IORT on local control, disease-free survival and OS. Additional data are needed to determine the effect of adjunctive IORT for
locally advanced rectal tumors with greater certainty. National Comprehensive Cancer Network guidelines suggest use of IORT in patients with T4 or recurrent cancers as an additional boost. Outside of those parameters, the evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have gastric cancer who receive adjunctive IORT, the evidence includes RCTs and a systematic review of RCTs. Relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. A meta-analysis of 8 RCTs found a benefit of IORT in locoregional control (but not OS) when used with EBRT. When IORT was administered without adjuvant EBRT in patients with stage III disease, OS improved. Thus, IORT might be considered an alternative to EBRT in patients undergoing surgery for stage III gastric cancer. Randomized studies comparing the benefits and harms of the 2 treatments are needed to determine the efficacy of IORT with greater certainty. It cannot be determined whether IORT provides any benefit for OS in this patient population (gastric cancer patients) when used with EBRT. Further study is needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have soft tissue sarcomas who receive adjunctive IORT, the evidence includes a systematic review, a small RCT, and several nonrandomized comparative studies. Relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. Overall, the study quality is low. The limited data suggest that IORT might improve local control and OS but adverse events might outweigh any treatment benefit. RCTs are needed to determine the risks and benefits of IORT for soft tissue sarcomas with greater certainty. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have gynecologic cancers who receive adjunctive IORT, the evidence includes a nonrandomized trial and case series. Relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. The contribution of adjuvant IORT cannot be determined from the available literature. There is no evidence that IORT improves survival rates, and there may be severe complications related to the therapy. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have head and neck cancers who receive adjunctive IORT, the evidence includes case series. Relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. The strongest evidence is from a retrospective analysis of patients who had recurrent salivary gland carcinomas and were at risk of radiation toxicity due to prior treatment with EBRT. Some patients received IORT plus salvage surgery, and multivariate analysis found that the use of IORT was a significant predictor of improved outcomes. Although these findings suggested an improvement in health outcomes for head and neck cancers that cannot be treated with EBRT due to toxicity, there was a high-risk of selection bias in this study. Comparative trials are needed to determine the efficacy of IORT with greater certainty. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have pancreatic cancer who receive adjunctive IORT, the evidence includes large case series, cohort studies, and systematic reviews of these studies. Relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. The systematic review found that in patients with resectable pancreatic cancer the addition of IORT to standard therapy was associated with improved median survival and reduced local recurrence; the evidence was limited by mostly smaller retrospective designs contributing to the review. However, the vast majority of patients present at diagnosis with more advanced disease, such as borderline resectable, locally advanced, or with distant metastases, where comparative evidence is limited to case series. More data are needed to determine the effect of adjunctive IORT for resectable, locally advanced and metastatic pancreatic cancer with greater certainty. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have renal cell carcinoma who receive adjunctive IORT, the evidence includes case series. Relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. No controlled trials were identified to determine whether adjunctive IORT improves
health outcomes when added to multimodal therapy with surgical resection and EBRT. Grade 3 or higher toxicity after IORT has been reported in a substantial percentage of patients. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have glioblastoma or neuroblastoma or fibromatosis who receive adjunctive IORT, the evidence includes case series. Relevant outcomes are OS, disease-specific survival, change in disease status, and treatment-related morbidity. Compared with other therapies, it is unclear whether IORT improves OS. However, compared with historical controls, IORT for patients with previously untreated malignant gliomas had no survival benefit when given in conjunction with multimodal therapy. In addition, complication rates may be high. Comparative trials are needed to evaluate the safety and efficacy of this treatment modality. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>3/2018</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>1/2017</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>11/2015</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>9/2015</td>
<td>Clarified coding information.</td>
</tr>
<tr>
<td>10/2014</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>8/2014</td>
<td>Coding information clarified.</td>
</tr>
<tr>
<td>12/2013</td>
<td>New references from BCBSA National medical policy.</td>
</tr>
<tr>
<td>5/2009</td>
<td>BCBSA National medical policy review. No changes to policy statements.</td>
</tr>
<tr>
<td>8/2008</td>
<td>BCBSA National medical policy review. No changes to policy statements.</td>
</tr>
<tr>
<td>7/2007</td>
<td>BCBSA National medical policy review. No changes to policy statements.</td>
</tr>
</tbody>
</table>

**Information Pertaining to All Blue Cross Blue Shield Medical Policies**
Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)
References


